ACHE and Alzheimer disease: By far, the most attractive approach to AD treatment involves the development of drugs that in one way or another affect the stability, removal, or aggregation of Aβ, and clinically available pharmacotherapies of AD include acetylcholinesterase (AChE) inhibitors and N‐methyl‐D‐aspartate (NMDA) receptor antagonists (Bachurin, Bovina, & Ustyugov, 2017).